144 ·Filed Jun 1, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001950047-26-005336
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine Form 144 filing by a director following a consistent monthly sale pattern. No material signal for the stock. Monitor for any acceleration in insider selling volume or unexpected C-suite filings, but this filing alone warrants no action.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
MIRM ▲ +6.88% at T+60d
NEUTRAL call ✓ call won +6.88% · α vs SPY +5.76% · entry $92.17 → $98.51
Entry anchored
Jun 1, 03:59 PM ET
via exchange tick
T+1d
-0.36%
call -0.36% · α +0.33%
$91.84
settled 4mo ago
T+5d
+3.59%
call +3.59% · α +6.56%
$95.48
settled 4mo ago
T+20d
+30.69%
call +30.69% · α +32.26%
$120.46
settled 3mo ago
T+60d
+6.88%
call +6.88% · α +5.76%
$98.51
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Director Saira Ramasastry filed a Form 144 notice of intent to sell 3,977 shares of Mirum Pharmaceuticals common stock, valued at approximately $397,700 based on the filing date. This is a modest sale relative to the company's $6.2B market cap and follows a pattern of regular monthly sales by the director (2,000 shares each in March, April, and May 2026). The filing is routine and does not signal material insider concern.

Key Facts

  • Director Saira Ramasastry filed Form 144 to sell 3,977 shares of MIRM common stock.
  • Estimated sale value is approximately $397,700 based on filing date.
  • Ramasastry has sold 2,000 shares per month in March, April, and May 2026, suggesting a pre-planned trading pattern.
  • The sale represents a tiny fraction of the company's $6.2B market cap.
  • Recent insider activity shows only 1 sell totaling $219K in the past 30 days, consistent with routine diversification.

Financial Impact

~$397,700 sale by a director, immaterial relative to $6.2B market cap

insider holdings

Risk Factors

  • No material risk identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (17 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-005336
Document: 0001950047-26-005336-index.html0001950047-26-005336
Document: 0001950047-26-005336.txt0001950047-26-005336
16 reports for MIRM
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+20▲ +28.29%Jun 11, 2026
Filters
Rows
Reports for MIRM — sortable, filterable
TypeNow
Aug 19, 2026
6w ago
Insider Cluster
NEUTRAL ★ 3/10
$102.24 $98.82▼ −3.35%▼ −1.39%$82.58 (−19.23%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 3/10
$98.97 $100.61▲ +1.66%▲ +3.55%$82.58 (−16.56%)
Aug 11, 2026
7w ago
Insider Cluster
BEARISH ★ 5/10
$98.97 $100.61▼ −1.66%▼ −3.55%$82.58 (+16.56%)
Aug 10, 2026
7w ago
144
NEUTRAL ★ 3/10
$98.23 $98.30▲ +0.07%▲ +1.13%$82.58 (−15.93%)
Aug 5, 2026
8w ago
8-K
MIXED ★ 6/10
$94.12 $100.63▲ +6.92%▲ +6.32%$82.58 (−12.26%)
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 2/10
$128.57 $105.79▼ −17.72%▼ −20.99%$82.58 (−35.77%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$99.54 $127.70▲ +28.29%▲ +26.40%$82.58 (−17.04%)
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$94.00 $127.70▲ +35.85%▲ +32.23%$82.58 (−12.15%)
Jun 2, 2026
17w ago
Insider Cluster
NEUTRAL ★ 2/10
$91.84 $125.59▲ +36.76%▲ +37.76%$82.58 (−10.08%)
Jun 1, 2026
17w ago
144
NEUTRAL ★ 3/10
$92.17 $120.46▲ +30.69%▲ +32.26%$82.58 (−10.40%)
Showing 10 of 16

US Market Status

Market Open — Closes in 46m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access